about the author

Reynald Castañeda

Deputy Editor

rcastaneda@endpointsnews.com
Reynald Castañeda on LinkedIn

Reynald Castañeda is a deputy editor for Endpoints News. Reynald has 10 years’ journalism experience covering pharma and healthcare: from generating data-led analysis on strategy and operations as the lead editor for Clinical Trials Arena, to writing long-form features and scoops as an investigative journalist for GlobalData Insights. His reporting paved the way to roles at Reuters Insight as the head of pharma research and at Economist Impact as a Covid-19 vaccine development consultant. Born in the Philippines with formative years spent in New Zealand, he is currently based in London, UK.

author articles

No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Last year
R&D

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Last year
R&D

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
R&D
Pharma

Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Last year
R&D

GSK, Pfiz­er head in­to patent du­el in high-stakes RSV vac­cine war

Last year
Pharma
Law

Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Last year
R&D

As­traZeneca picks up Pfiz­er’s rare dis­ease gene ther­a­pies, taps new R&D leader as Mene Pan­ga­los steps down

Last year
People
Deals

GSK bull­ish on RSV vac­cine bat­tle against Pfiz­er, ships first Arexvy dose

Last year
Pharma
Marketing

GSK pulls plans to mar­ket ane­mia drug in EU and oth­er mar­kets, cit­ing 're­duced op­por­tu­ni­ty'

Last year
Pharma
First page Previous page 1234
A service from the Financial Times